Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post‐dosing: analysis of suitability for opioid overdose reversal

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Addiction

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/add.13849PMID 28430384
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• STATISTICAL CONSIDERATIONS

  2019cited by this paper
• Training and administration of epinephrine auto-injectors for anaphylaxis treatment in US schools: results from the EpiPen4Schools® pilot survey

  2016cited by this paper
• The toxicology of heroin-related death: estimating survival times.

  2016cited by this paper
• Pharmacokinetic Properties and Human Use Characteristics of an FDA‐Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose

  2016cited by this paper
• Commentary on Darke & Duflou (2016): Heroin-related deaths-identifying a window for intervention.

  2016cited by this paper
• Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?

  2016cited by this paper
• Take-home emergency naloxone to prevent deaths from heroin overdose

  2014influential reference
• Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal

  2013influential reference
• Population Pharmacokinetics of Intravenous, Intramuscular, and Intranasal Naloxone in Human Volunteers

  2008cited by this paper
• Prescription naloxone: a novel approach to heroin overdose prevention.

  2007influential reference
• Naloxone in opioid poisoning: walking the tightrope

  2005cited by this paper
• Extended Release Oral Dosage Forms‚ÄîDevelopment,Evaluation, and Application of In Vitro/In Vivo Correlations

  2001cited by this paper
• Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose.

  1998cited by this paper
• The distribution of naloxone to heroin users.

  1997cited by this paper
• Heroin overdose: the case for take-home naloxone

  1996influential reference

• Biopharmaceutical assessment of naloxone permeation through human respiratory epithelial tissues: A chromatographic-mass spectrometric approach with cloud based aerosol dosing and delivery.

  2026cites this paper
• Whole body physiology model to simulate respiratory depression of fentanyl and associated naloxone reversal

  2024cites this paper
• High-dose naloxone formulations are not as essential as we thought

  2024cites this paper
• Whole Body PBPK Model of Nasal Naloxone Administration to Measure Repeat Dosing Requirements During Fentanyl Overdose

  2023cites this paper
• High-Dose Naloxone Formulations Are Not as Essential as We Thought

  2023cites this paper
• Take-Home Naloxone and the Prevention of Deaths from Heroin Overdose: Pursuing Strong Science, Fuller Understanding, Greater Impact

  2021cites this paper
• Intranasal Naloxone Administration.

  2021cites this paper
• Implementing Harm Reduction Strategies to Reduce Opioid Overdoses

  2021cites this paper
• Benefits and barriers associated with take-home-naloxone in the view of Italian service providers

  2021cites this paper
• Prepacked naloxone administration for suspected opioid overdose in the era of illicitly manufactured fentanyl: a retrospective study of regional poison center data

  2020cites this paper
• Disparity in Naloxone Availability and the Impact of Sociodemographic Determinants.

  2020cites this paper
• Medication Treatment of Opioid Use Disorder.

  2020cites this paper
• Protocol for a multi-site study of the effects of overdose prevention education with naloxone distribution program in Skåne County, Sweden

  2020cites this paper
• Endogenous Opiates and Behavior: 2017.

  2019cites this paper
• Effect of Formulation Variables on the Nasal Permeability and Stability of Naloxone Intranasal Formulations

  2019cites this paper
• Pharmacokinetics and pharmacodynamics of intranasal and intravenous naloxone hydrochloride administration in healthy dogs.

  2019cites this paper
• The lived experience of 'opioid use disorder' in Ireland in the 21st century

  2019cites this paper
• Increasing Naloxone Co-prescription for Patients on Chronic Opioids: a Student-Led Initiative

  2018cites this paper
• Naloxone nasal spray (Nyxoid®) in opioid overdose: a profile of its use in the EU

  2018cites this paper
• Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa

  2018cites this paper
• Naloxone nasal spray (Nyxoid®) in opioid overdose: a profile of its use in the EU

  2018cites this paper
• Naloxone dosage for opioid reversal: current evidence and clinical implications

  2018cites this paper
• Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review.

  2018cites this paper
• Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.

  2018cites this paper
• Intranasal naloxone and related strategies for opioid overdose intervention by nonmedical personnel: a review

  2017cites this paper
• Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study*

  2017cites this paper